Cargando…

Haematological manifestations of lupus

Our purpose was to compile information on the haematological manifestations of systemic lupus erythematosus (SLE), namely leucopenia, lymphopenia, thrombocytopenia, autoimmune haemolytic anaemia (AIHA), thrombotic thrombocytopenic purpura (TTP) and myelofibrosis. During our search of the English-lan...

Descripción completa

Detalles Bibliográficos
Autores principales: Fayyaz, Anum, Igoe, Ann, Kurien, Biji T, Danda, Debashish, James, Judith A, Stafford, Haraldine A, Scofield, R Hal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378375/
https://www.ncbi.nlm.nih.gov/pubmed/25861458
http://dx.doi.org/10.1136/lupus-2014-000078
_version_ 1782364060579266560
author Fayyaz, Anum
Igoe, Ann
Kurien, Biji T
Danda, Debashish
James, Judith A
Stafford, Haraldine A
Scofield, R Hal
author_facet Fayyaz, Anum
Igoe, Ann
Kurien, Biji T
Danda, Debashish
James, Judith A
Stafford, Haraldine A
Scofield, R Hal
author_sort Fayyaz, Anum
collection PubMed
description Our purpose was to compile information on the haematological manifestations of systemic lupus erythematosus (SLE), namely leucopenia, lymphopenia, thrombocytopenia, autoimmune haemolytic anaemia (AIHA), thrombotic thrombocytopenic purpura (TTP) and myelofibrosis. During our search of the English-language MEDLINE sources, we did not place a date-of-publication constraint. Hence, we have reviewed previous as well as most recent studies with the subject heading SLE in combination with each manifestation. Neutropenia can lead to morbidity and mortality from increased susceptibility to infection. Severe neutropenia can be successfully treated with granulocyte colony-stimulating factor. While related to disease activity, there is no specific therapy for lymphopenia. Severe lymphopenia may require the use of prophylactic therapy to prevent select opportunistic infections. Isolated idiopathic thrombocytopenic purpura maybe the first manifestation of SLE by months or even years. Some manifestations of lupus occur more frequently in association with low platelet count in these patients, for example, neuropsychiatric manifestation, haemolytic anaemia, the antiphospholipid syndrome and renal disease. Thrombocytopenia can be regarded as an important prognostic indicator of survival in patients with SLE. Medical, surgical and biological treatment modalities are reviewed for this manifestation. First-line therapy remains glucocorticoids. Through our review, we conclude glucocorticoids do produce a response in majority of patients initially, but sustained response to therapy is unlikely. Glucocorticoids are used as first-line therapy in patients with SLE with AIHA, but there is no conclusive evidence to guide second-line therapy. Rituximab is promising in refractory and non-responding AIHA. TTP is not recognised as a criteria for classification of SLE, but there is a considerable overlap between the presenting features of TTP and SLE, and a few patients with SLE have concurrent TTP. Myelofibrosis is an uncommon yet well-documented manifestation of SLE. We have compiled the cases that were reported in MEDLINE sources.
format Online
Article
Text
id pubmed-4378375
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-43783752015-04-08 Haematological manifestations of lupus Fayyaz, Anum Igoe, Ann Kurien, Biji T Danda, Debashish James, Judith A Stafford, Haraldine A Scofield, R Hal Lupus Sci Med Review Our purpose was to compile information on the haematological manifestations of systemic lupus erythematosus (SLE), namely leucopenia, lymphopenia, thrombocytopenia, autoimmune haemolytic anaemia (AIHA), thrombotic thrombocytopenic purpura (TTP) and myelofibrosis. During our search of the English-language MEDLINE sources, we did not place a date-of-publication constraint. Hence, we have reviewed previous as well as most recent studies with the subject heading SLE in combination with each manifestation. Neutropenia can lead to morbidity and mortality from increased susceptibility to infection. Severe neutropenia can be successfully treated with granulocyte colony-stimulating factor. While related to disease activity, there is no specific therapy for lymphopenia. Severe lymphopenia may require the use of prophylactic therapy to prevent select opportunistic infections. Isolated idiopathic thrombocytopenic purpura maybe the first manifestation of SLE by months or even years. Some manifestations of lupus occur more frequently in association with low platelet count in these patients, for example, neuropsychiatric manifestation, haemolytic anaemia, the antiphospholipid syndrome and renal disease. Thrombocytopenia can be regarded as an important prognostic indicator of survival in patients with SLE. Medical, surgical and biological treatment modalities are reviewed for this manifestation. First-line therapy remains glucocorticoids. Through our review, we conclude glucocorticoids do produce a response in majority of patients initially, but sustained response to therapy is unlikely. Glucocorticoids are used as first-line therapy in patients with SLE with AIHA, but there is no conclusive evidence to guide second-line therapy. Rituximab is promising in refractory and non-responding AIHA. TTP is not recognised as a criteria for classification of SLE, but there is a considerable overlap between the presenting features of TTP and SLE, and a few patients with SLE have concurrent TTP. Myelofibrosis is an uncommon yet well-documented manifestation of SLE. We have compiled the cases that were reported in MEDLINE sources. BMJ Publishing Group 2015-03-03 /pmc/articles/PMC4378375/ /pubmed/25861458 http://dx.doi.org/10.1136/lupus-2014-000078 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Review
Fayyaz, Anum
Igoe, Ann
Kurien, Biji T
Danda, Debashish
James, Judith A
Stafford, Haraldine A
Scofield, R Hal
Haematological manifestations of lupus
title Haematological manifestations of lupus
title_full Haematological manifestations of lupus
title_fullStr Haematological manifestations of lupus
title_full_unstemmed Haematological manifestations of lupus
title_short Haematological manifestations of lupus
title_sort haematological manifestations of lupus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378375/
https://www.ncbi.nlm.nih.gov/pubmed/25861458
http://dx.doi.org/10.1136/lupus-2014-000078
work_keys_str_mv AT fayyazanum haematologicalmanifestationsoflupus
AT igoeann haematologicalmanifestationsoflupus
AT kurienbijit haematologicalmanifestationsoflupus
AT dandadebashish haematologicalmanifestationsoflupus
AT jamesjuditha haematologicalmanifestationsoflupus
AT staffordharaldinea haematologicalmanifestationsoflupus
AT scofieldrhal haematologicalmanifestationsoflupus